In a large prospective study conducted by Levine et al. the impact of Oncotype Dx on the patient’s CT preference was assessed in the same category of ER + /HER2- breast cancer patients and they reported a comparable 31% change in the patient’s CT treatment choice following Oncotype Dx. This evidence concerns the gene ERBB2 and breast carcinoma.